|
Ellagic Acid, Urolithins and Colonic Microbial Communities Affected by Walnut Consumption
|
|
19-121JS-1
|
|
Ellagic Acid, Urolithins and Colonic Microbial Communities Affected by Walnut Consumption
|
|
Dr. Daniel Rosenberg
|
|
The purpose of this study is to investigate whether adding walnuts to your diet can have a beneficial effect on your colon. Walnuts contain a natural compound called ellagitannin that is broken down in the stomach to ellagic acid. Ellagic acid is further broken down by your gut microbiota into a group of polyphenolic compounds called urolithins that have powerful anti-inflammatory actions. The gut microbiota is defined as the community of bacteria, fungi, viruses, etc. that live in your gut. Increasing evidence suggests that polyphenol consumption is associated with lower risk of colorectal cancer. We aim to investigate how a person's gut microbiome may contribute to your ability to form these powerful antioxidant urolithin compounds. Antioxidants are a group of substances that have the ability to reduce inflammation. In this study, we will collect demographic information and dietary records, and perform tests on proteins, DNA and/or RNA from samples of colon biopsies, blood, stool and urine to investigate how a person's microbiome may contribute to their ability to form urolithins.
|
Cancer - Gastrointestinal
|
|
Gastrointestinal (Stomach, Bowel, Etc.)
|
|
Healthy Volunteer
|
|
Nutrition/Metabolism/Exercise
|
|
|
Subjects eligible for inclusion in this study must meet all of the following criteria:
• Men or women between the ages of 50-65 years old who are scheduled to undergo a routine screening colonoscopy
• English speaking/reading patients willing and able to provide written informed consent for study participation
• Patients willing to consume walnuts for 3 weeks
• Willingness to comply with all study requirements
A subject will not be eligible for inclusion in the study if any of the following criteria apply:
• Current active malignancy, previous history of gastrointestinal malignancy, or altered gastrointestinal anatomy
• Current evidence or previous history of ulcerative colitis or Crohn’s disease
• HIV infection, chronic viral hepatitis
• Allergy to walnuts or hypersensitivity to tree nuts
• Use of antibiotics within the past month
• Individuals with blood coagulation disorders or on anti-coagulant therapy
• Treated with steroids, immunosuppressive agents or other anti-inflammatory drugs one week prior to starting intervention
• Non-English-speaking patients who require an interpreter to give consent
• Patients residing in the Department of Correction
• Inability to comply with the protocol requirements
• Any other condition that, in the opinion of the PI, might interfere with study objectives
|
|
Amy Pallotti. Telephone: 860-679-3878. Email: apallotti@uchc.edu
|
|
Enrolling/recruiting. For current recruitment status, please check with study contact.
|
|
|